Nature.com spotlights Saisei Pharma MAF research on aging

By AI, Created 5:31 AM UTC, June 02, 2026, /AGP/ – Nature.com’s Nutrition Spotlight has featured Saisei Pharma research on dietary MAF and its possible links to healthy aging, muscle health, telomeres and longevity pathways. The coverage puts a public spotlight on the company’s Japan-based work and the MAF series food products distributed in Australia and New Zealand.

Why it matters: - Nature.com’s coverage gives Saisei Pharma a broader public platform for research tied to nutrition, immunity and age-related biology. - The feature could help consumers and wellness audiences understand the research base behind Saisei Pharma’s MAF series food products. - The work sits at the intersection of healthy aging, sarcopenia and longevity research, where human data remain limited.

What happened: - Saisei Australia Pty Ltd said Nature.com published a Spotlight: Nutrition article, “Exploring links between nutrition and longevity,” featuring Saisei Pharma’s research on macrophage activating factor, or MAF. - The article examines whether dietary MAF may affect biological pathways linked to healthy aging. - The feature highlights Saisei Pharma’s research into sarcopenia, telomeres, IGF-1 and Klotho-related longevity mechanisms. - Saisei Australia said the coverage helps connect customers with publicly available research behind Saisei Pharma’s MAF series food products.

The details: - MAF is described as an immune-related protein that helps activate macrophages, the white blood cells that clear dead or damaged cells and harmful pathogens. - Saisei Pharma researchers are studying whether adding MAF to the diet may influence age-related biological changes. - The Nature.com feature cites collaborations with researchers at the National Hospital Organization Kyoto Medical Center, Tokushima University, Konan University, Tottori University and Hiroshima University. - Those collaborations include preclinical and clinical studies on sarcopenia and other proteins and genes linked to aging. - Sarcopenia is an age-related decline in muscle mass and strength, and it is associated with frailty, falls, fractures and physical disability. - Saisei Pharma and collaborators are studying whether MAF supplementation may affect muscle atrophy factors, muscle growth factors and motor coordination. - A clinical trial in Osaka is measuring whether Saisei Pharma’s MAF supplement changes circulating IGF-1 levels, a hormone tied to muscle growth and repair. - Dr. Toshio Inui, co-founder of Saisei Pharma, called IGF-1 a “very strong, protective action against sarcopenia” in the Nature.com article. - The feature says mouse studies found oral MAF slightly lengthened telomeres and increased expression of telomerase-related components. - Saisei Pharma is now studying 161 human participants in Japan, ages 40 and above, to see whether orally administered MAF taken for three or six months affects telomere length. - The article also discusses Klotho, a gene and hormone associated with longevity-related pathways. - According to the feature, Saisei Pharma’s mouse research suggests MAF may trigger overexpression of Klotho in the blood, brain and kidneys. - Researchers are exploring whether similar Klotho-related effects appear in humans. - Saisei’s MAF series is based on patented Japanese technology developed within the Saisei group. - Saisei Australia said the products are manufactured in Japan. - Saisei Australia provides access to Saisei Pharma’s MAF series food products for customers across Australia and New Zealand. - The company said it also supports access to publicly available research and educational information related to healthy aging and longevity. - Saisei Australia said it provides local presence, product access and customer support in the region. - Saisei Pharma is headquartered in Osaka, Japan. - The company develops patented food-based technologies and studies nutrition, health, longevity, healthy aging, immune function, cognitive decline and muscle health.

Between the lines: - The Nature.com feature frames Saisei Pharma’s work as part of a broader scientific search for dietary interventions that may influence aging biology. - The research mix spans animal studies and human trials, which suggests the company is still building evidence for how MAF may work in people. - The inclusion of telomeres, IGF-1 and Klotho signals an effort to connect one product platform to multiple aging-related pathways. - The article also elevates Saisei Australia’s role as a regional distributor and information channel, not a medical provider. - Saisei Australia said it does not provide patient care or medical treatment and does not operate as a clinic in Australia.

What’s next: - Saisei Pharma’s human telomere study in Japan will be one of the next key data points for the company’s MAF research program. - Results from the Osaka IGF-1 trial could help clarify whether MAF has measurable effects on muscle-related biomarkers. - Further work on Klotho and sarcopenia may determine whether the animal-study findings translate to people. - The full Nature.com Spotlight: Nutrition article is available on Nature.com.